MedPath

A double blind, randomized placebo-controlled cross-over study on the cardiovascular effects of Salvia miltiorrhiza extract (Danshen) in patients with hypertension and hyperlipidemia

Conditions
elevated levels of lipids in the blood
hyperlipidemia
10013317
10057166
Registration Number
NL-OMON35218
Lead Sponsor
niversitair Medisch Centrum Sint Radboud
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

* Age: 40-70 (50% men / 50% women)
* Women:
- postmenopausal, or
- use of contraceptive pill
* Hyperlipidemia
- elevated level of triglycerides: > 1.7 mmol/L
- elevated level of LDL-cholesterol: > 3.5 mmol/L
- reduced level of HDL-cholesterol: < 1.03 mmol/L
* Hypertension:
- systolic pressure > 90 mm Hg
- diastolic pressure > 140 mm Hg
* Signed informed consent

Exclusion Criteria

* Smoking
* Alcohol or drug abuse
* History of cardiovascular disease (myocard infarct, angina pectoris, CVA, CI)
* Diabetes mellitus
* Pregnancy
* Concomitant (chronic) use of:
- ACE-inhibitors
- Statins
- Anticoagulant drugs
- > 1 antihypertensive drug
- High-dose antihypertensive medication (above defined daily dose)
- (Antioxidant) vitamin supplements
* Clinically significant liver disease (3 times the upper normal limit of ALAT,ASAT,AF, *GT or LDH)
* Clinically significant anemia (male Hb < 6,9 mmol/L, female < 6,25 mmol/L)
* Abnormal creatinine clearance (adjusted for age of subject)
* Participation to any drug-investigation during the previous 90 days

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Outcome parameters will be assessed in the 4th week of each treatment period.<br /><br>To study the effect of Danshen on hyperlipidemia, in particular<br /><br>LDL-cholesterol, but also HDL-cholesterol, total cholesterol, total<br /><br>triglycerides, apolipoprotein B plasma levels and LDL oxidation will be<br /><br>measured.</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath